Pharmacopeia Inc.

Merck Sharp + Dohme Corp.

Schering Corporation

Zhenmin He

Viyyoor Moopil Girijavallabhan

Ronald J Doll

Lawrence Wayne Dillard

Timothy J Guzi

Michael P Dwyer

Kamil Paruch

Vinh D Tran

Ray Anthony James

Haengsoon Park

Alan K Mallams

Vincent Stewart Madison

Vidyadhar Madhav Paradkar

Tin-Yau Chan

Douglas Walsh Hobbs

Thierry Olivier Fischmann

Carmen S Alvarez

Kartik M Keertikar

Jocelyn Rivera

Paul Kirschmeier

Rajat Bannerji

In its many embodiments, the present invention provides a method of inhibiting one or more cyclin dependent kinases in a patient comprising administering to said patient a therapeutically effective amount of at least one pyrazolo[1,5-a]pyrimidine compound or a pharmaceutical composition comprising such compound, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An example pyrazolo[1,5-a]pyrimidine compound useful in the present invention is shown below: 

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Growing community of inventors

Shanghai, China

Zhenmin He